Holmium-166 radioembolisation dosimetry in HCC.

ABSTRACT:

Purpose

To evaluate dosimetry, dose-response and dose-toxicity relationships for holmium-166 (¹⁶⁶Ho) radioembolisation in patients with hepatocellular carcinoma (HCC).

Methods

Thirty-one patients with hepatocellular carcinoma were included in the HEPAR Primary study (NCT03379844, registered on December 20th, 2017) and underwent ¹⁶⁶Ho-microspheres radioembolisation. Linear mixed models assessed the association between tumour absorbed doses and response based on mRECIST both on tumour and patient level. Preliminary tumour absorbed dose thresholds were estimated based on predictive value. Linear regression models assessed the association between non-tumour absorbed dose and Common Terminology Criteria for Adverse Events version 4.03.

Results

Median

SUBMITTER: Reinders MTM 

PROVIDER: S-EPMC11754330 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature